InvestSMART

CSL Limited (ASX:CSL)

ALERT: Price-sensitive ASX Announcement for CSL
Current share price for CSL : $127.930 8.05 (6.72%)+
Announcement
Release
11 May 2026 8:15AM
Price at Release
$119.880
Full Release
download
Summary
CSL Limited's Interim CEO, Gordon Naylor, provided a comprehensive 90-day review of the company's performance along with a financial update. The review highlighted the need to accelerate execution of growth initiatives, as past outcomes have not met expectations, affecting both growth and investor confidence. Despite challenges, CSL maintains a strong cash flow and financial capacity. The company is focused on transforming its operations to restore profitable growth, with improvements in plasma collection and influenza vaccine sectors. An updated FY26 outlook projects revenue around $15.2 billion and NPATA of $3.1 billion, though financial benefits from initiatives are expected to materialize slower than anticipated. The company also plans significant non-cash pre-tax asset impairments totaling approximately $5 billion over FY26 and FY27. Leadership changes include the retirement of Andy Schmeltz and the appointment of Diego Sacristan as Chief Commercial Officer.
Key Points
  • Interim CEO 90-day review highlights the need for accelerated execution.
  • CSL maintains strong cash flow and financial capacity.
  • Updated FY26 revenue outlook of $15.2 billion and NPATA $3.1 billion.
  • Challenges include unmet expectations affecting growth and confidence.
  • Significant asset impairments expected across FY26 and FY27.
  • Leadership changes with Andy Schmeltz retiring and Diego Sacristan appointed.
  • Focus on plasma collection and influenza vaccines.
  • Financial benefits from growth initiatives expected to take longer to materialize.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.